Phase Ib study of eltrombopag and azacitidine in patients with high‐risk myelodysplastic syndromes and related disorders (the ELASTIC study)

Summary Treating adverse risk myelodysplastic syndromes with azacitidine exacerbates thrombocytopenia. We report a study of eltrombopag in combination with azacitidine using a 3 + 3 cohort design. Patients with baseline platelets of

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of haematology 2022-10, Vol.199 (2), p.222-229
Hauptverfasser:	Sternberg, Alexander, Boucher, Rebecca, Coulthard, Helen Chantal, Raghavan, Manoj, Culligan, Dominic, Jackson, Aimee, Cargo, Catherine, Dennis, Mike, Metzner, Marlen, O'Sullivan, Jennifer, Moore, Rachel, Bowen, David, Vyas, Paresh
Format:	Artikel
Sprache:	eng
Schlagworte:	azacitidine Azacitidine - therapeutic use Benzoates - therapeutic use Bone marrow Drug Combinations eltrombopag Hematology Humans Hydrazines - therapeutic use Myelodysplastic syndrome myelodysplastic syndromes (MDS) Myelodysplastic Syndromes - drug therapy Patients Platelets Pyrazoles - therapeutic use Thrombocytopenia Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary Treating adverse risk myelodysplastic syndromes with azacitidine exacerbates thrombocytopenia. We report a study of eltrombopag in combination with azacitidine using a 3 + 3 cohort design. Patients with baseline platelets of
ISSN:	0007-1048 1365-2141
DOI:	10.1111/bjh.18389